VICENT MWESIGYE
ID: UNCST-2024-R002866
|
LYMPHEDEMA: CAUSATIVE AGENTS, PATIENT AND CARETAKER KNOWLEDGE, SELF-REPORTED HEALTHCARE NEEDS AND PREVENTIVE STRATEGIES IN KAMWENGE DISTRICT.
REFNo: HS5335ES
3. To explore the lymphedema-related knowledge, lived experiences and healthcare needs of patients and their caretakers and preventive strategies in Kamwenge district, South Western Uganda.,2. To determine the causative agents of lymphedema among patients with lymphedema in Kamwenge district, South Western Uganda.,1. To describe the Preventive strategies, their effectiveness in patients with Lymphedema based on Scoping review globally.,To determine the causative agents, patient and caretaker knowledge, self-reported healthcare needs and preventive strategies amongst Lymphedema patients in Kamwenge District South Western Uganda.,
|
Uganda |
2024-12-10 14:35:45 |
2027-12-10 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease (IMR-SCD-301)
REFNo: HS1119ES
Primary Objectives:
1. To evaluate the HbF response to IMR-687 versus placebo
2. To evaluate the safety of IMR-687 versus placebo
Secondary Efficacy Objectives:
1. To evaluate the effect of IMR-687 versus placebo on HbF-associated biomarkers
2. To evaluate the effect of IMR-687 versus placebo on indices of red cell hemolysis
3. To evaluate the effect of IMR-687 versus placebo on indices of RBC adhesion
4. To evaluate the effect of IMR-687 versus placebo on the incidence of VOCs
5. To evaluate the effect of IMR-687 versus placebo on quality of life (QoL) measures
Pharmacokinetic Objectives:
To evaluate the PK of IMR-687 and any major circulating metabolites
Exploratory Efficacy Objectives:
1. To evaluate the effect of IMR-687 versus placebo on changes in RBC characteristics and total Hb
2. To evaluate the effect of IMR-687 versus placebo on renal function
3. To evaluate the effect of IMR-687 versus placebo on indices associated with cardiovascular pathophysiology and ischemic stroke risk
|
Uganda |
2021-02-05 |
2024-02-05 |
Medical and Health Sciences |
|
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
A randomized Trial to investigate strategies to reduce mortality among HIV-infected and HIV-exposed children admitted with severe acute malnutrition in Mulago Hospital, Kampala, Uganda
REFNo: HS1277ES
Primary objective
1. To investigate whether empirical use of an antibiotic with greater antimicrobial sensitivity (ceftriaxone) than standard of care (ampicillin plus gentamicin) will reduce mortality among 300 HIV-infected and HEU children admitted with severe acute malnutrition at Mwanamugimu Nutrition Unit, Mulago Hospital in a randomised controlled trial.
Secondary objectives
2. To compare the length of hospitalization, weight-for-height, weight-for-age and height-for-age z-scores between ceftriaxone versus standard of care (ampicillin and gentamicin) treatment arms.
3. To ascertain the frequency of different bloodstream bacterial pathogens and their antimicrobial sensitivities among HIV-infected and HEU children admitted with severe acute malnutrition at Mwanamugimu Nutrition Unit, Mulago Hospital participating in the randomised trial.
4. To ascertain the prevalence of, and factors associated with, HIV-infection among children admitted with severe acute malnutrition at Mwanamugimu Nutrition Unit, Mulago Hospital in light of improved PMTCT approaches in a cross-sectional evaluation at admission, among 280 children.
5. To evaluate the pharmacokinetic (PK) parameters of LPV/r among severely malnourished HIV infected children using sparse PK samples. The PK parameter values obtained will then be used in pharmacokinetic-pharmacodynamic (PK-PD) models to determine a possible optimal dose of LPV/r among severely malnourished children, which could then subsequently be evaluated in a clinical trial.
|
Uganda |
2021-04-13 |
2024-04-13 |
Medical and Health Sciences |
|
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
Building Resources to Assess Impaired Neurocognition in Children with HIV in Low and Middle Income Countries (BRAIN Child LMICs)
REFNo: HS2271ES
(1) Adapt NeuroScreen for Luganda-speaking children 5-12 years. (a) Through expert focus groups and multiple rounds of cognitive interviewing with children, determine necessary adaptations to make the NeuroScreen tests valid, acceptable and understandable to Luganda-speaking children, (b) implement
those adaptations in the app, (c) re-evaluate the adapted app with children, (d) examine its acceptability by clinical staff most likely to administer it, and (e) make further adaptations, as needed.
(2) Examine construct validity of the child version NeuroScreen tests. (a) Compare NeuroScreen test performance to gold standard neuropsychological test battery performance among Ugandan children 5-12 years with and without HIV, and (b) explore the relationship between performance on NeuroScreen and behavioral health.
|
Uganda |
2022-06-28 16:42:46 |
2025-06-28 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease
REFNo: HS5637ES
1. To demonstrate superiority of
treatment with etavopivat
versus placebo in adolescents
and adults with SCD.
2. To evaluate clinical efficacy
measures of etavopivat treatment
versus placebo in adolescents
and adults with SCD
3. To assess clinically meaningful
improvement in fatigue and
functional exercise capacity
and QOL measures of
adolescents and adults with
SCD taking etavopivat
treatment compared to placebo
|
Uganda |
2025-03-14 17:26:26 |
2028-03-14 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
Understanding Post-Discharge Mortality in children living with HIV who are hospitalized (SUPPORT1-PDM)
REFNo: HS6005ES
1. To assess the impact of an improved follow-up on reducing PDM in CLHIV
2. To evaluate the performance of disease severity biomarkers in this specific population to predict PDM
3. To analyze changes in serial measurements of CMV and potential association with PDM at day +360 in CLHIV
4. To describe the number of children with persistent detection of a specific respiratory pathogen
5. To describe the number of children with persistent detection of specific gastrointestinal (GI) pathogens
6. To describe the number of cases of histoplasmosis in CLHIV, its clinical characteristics, and outcomes in the identified cases, up to +360 days after discharge
7. To describe the prevalence of MDR colonization at enrollment, the microorganism isolated, and the duration of the colonization
8. To describe the main characteristics of readmissions, deaths and morbidity during 1-year follow-up after enrollment
|
Uganda |
2025-06-25 13:30:24 |
2028-06-25 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
Enhancing Novel Research for Inflammation and Cognitive Health among Adolescents and Young Adults Living with Perinatally Acquired HIV and Adversity (ENRICH+)
REFNo: HS6607ES
Specific Aim 1: Investigate differences in ID and NCI in demographically matched, virally suppressed PHIV and HHIV, as well as HUU AYA (15-25 years old) in Uganda while controlling for chronic adversities. Hypothesis 1 (H1): Both ID and NCI will be respectively higher in PHIV vs. HHIV vs. HUU AYA. H2: Within the two HIV groups, those with delayed ART initiation and lower nadir CD4 cell count at ART initiation will have higher ID and worse NCI.
Specific Aim 2: Investigate the relationship between ID and NCI in AYA within all three groups (PHIV, HHIV and HUU) controlling for chronic adversities. H3: There will be a positive association between ID and NCI in each group. H4: In a subset of PHIV and HUU AYA with prior repeated measures of ID, worsening trajectories of ID in PHIV across 6 years will be associated with worse NCI.
Specific Aim 3: Investigate the effects of co-occurring adversities (i.e., profiles) on the relationships between HIV, ID, and NCI. H5: Adversity profiles will be more severe respectively in PHIV vs. HHIV vs. HUU. H6: The strength of association between medical and psychosocial (e.g., stigma, mental health) adversities, ID and NCI will be strongest in PHIV vs. HHIV vs. HUU, respectively.
|
Uganda |
2025-10-29 16:07:10 |
2028-10-29 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Victor Musiime
ID: UNCST-2021-R013794
|
Experiences of caregivers and healthcare providers regarding post-discharge mortality and health-seeking behavior in life-threatening scenarios for children living with HIV in Uganda, Africa: a qualitative study
REFNo: HS7286ES
1. To explore experiences of caregivers and healthcare providers regarding PDM among children living with HIV after discharge from hospital.
2. To describe the role of social, cultural, economic and environmental context in health-seeking behavior after discharge for children living with HIV.
3. To explore perceived risk factors for post-discharge mortality among children living with HIV from the perspective of caregivers and health workers.
4. To describe strategies to prevent PDM among children living with HIV from the perspective of caregivers and health workers.
|
Uganda |
2026-04-02 12:46:45 |
2029-04-02 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
VINCENT MUBANGIZI
ID: UNCST-2024-R004232
|
Opti-MaP (Optimising Implementation of Maternal and Perinatal Death Surveillance and Response to prevent avoidable future deaths in Uganda
REFNo: HS4630ES
To review existing tools, develop and adapt a harmonised toolbox of resources to optimise MPDSR implementationTo co-design customised an "intervention package" using the toolboxTo evaluate effectiveness and cost-effectiveness of the "customised intervention package" to reduce perinatal and maternal mortalityTo develop and adapt a harmonised toolbox of resources to optimise MPDSR implementation
|
Uganda |
2024-08-06 18:02:24 |
2027-08-06 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
VINCENT MUBANGIZI
ID: UNCST-2024-R004232
|
RAMPS: REDUCING ALCOHOL PROBLEM DRINKING AND MALNUTRITION THROUGH INCOME-GENERATING PEER SUPPORT GROUPS
REFNo: HS5394ES
To document and evaluate the first peer support groups for men with alcohol problem drinking in Isingiro district
|
Uganda |
2025-02-20 17:49:15 |
2028-02-20 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Valence Mfitumukiza
ID: UNCST-2024-R004532
|
Enteric pathogens and intestinal injury in Ugandan children with malaria
RefNO: KABREC-2024-155
REFNo: HS4732ES
To examine the association of invasive enteric pathogens with stool and circulating host markers of intestinal and systemic inflammation,To define the frequency of common enteric pathogens among children with malaria and diarrhea, comparing to controls without malaria and/or diarrhea.,To characterize enteric pathogens in children with falciparum malaria and diarrhea as potential drivers of intestinal leak and systemic inflammation,
|
Uganda |
2024-10-31 15:49:23 |
2027-10-31 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Victor Lomonyang
ID: UNCST-2025-R017018
|
Prevalence of perceived stigma and associated factors among patients with tuberculosis (TB). A cross-sectional study in Napak district, Karamoja region, Uganda.
REFNo: HS6105ES
Overall Objective: To determine the prevalence of perceived stigma and associated factors among patients
with tuberculosis in Napak district, Karamoja region, Uganda.
Specific Objective 1: To determine the prevalence of perceived stigma among patients
with tuberculosis in Napak District.
Specific Objective 2: To identify the factors associated with perceived TB stigma among
patients with tuberculosis in Napak District.
|
Uganda |
2025-08-08 16:26:22 |
2028-08-08 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Violet Korutaro
ID: UNCST-2019-R000618
|
Baylor-IMPAACT-004: IMPAACT 2009; Protocol titled: Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants Ver
REFNo: HS252ES
a) Primary Objective for PK Component
• To determine the concentration of Tenofovir diphosphate (TDF-DP) associated with adequate adherence to FTC/TDF among women observed ingesting daily oral Prep during pregnancy and postpartum.
b) Secondary Objective for PK Component
• To compare TFV-DP concentrations observed in pregnant and postpartum women
c) Primary Objectives for PrEP Comparison Component
• To characterise PrEP adherence among HIV- uninfected young women during pregnancy and for twenty-six weeks postpartum, when provided with enhanced adherence support through mobile technology and counselling based on observed drug levels.
• To assess the safety of FTC/TDF for PrEP during pregnancy and postpartum by comparing pregnancy outcomes and maternal and infant safety between cohorts.
d) Other objectives for PrEP Comparison Component
• To identify individual, social and structural barriers and facilitators to PrEP uptake during pregnancy, and to adherence during pregnancy and postpartum.
• To compare reported sexual risk behaviours and incidence of sexually transmitted infection, among women who initiate PrEP during pregnancy versus women who decline PrEP.
• To compare antiretroviral drug resistance among women and infants who acquires HIV and without exposure to FTC/TDF for PrEP, including whether resistance was transmitted or acquired at time of transmission.
• To compare bone density in women who initiated PrEP during pregnancy and women who decline PrEP.
e) Exploratory Objective for PrEP Comparison Component
• To describe the composition of and changes in the maternal vaginal and gut microbiome and infant gut microbiome according to PrEP exposure.
|
Uganda |
2018-10-30 |
2021-10-30 |
Medical and Health Sciences |
|
Non-degree Award |
|
Violet Korutaro
ID: UNCST-2019-R000618
|
IMPAACT 2017: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. Short title: ‘MOCHA’ (More Options for Children and Adolescents), DAIDS # 30070, IND # 138,754
REFNo: HS1512ES
To assess the safety of CAB LA + RPV LA through Week 24 in HIV-infected, virologically suppressed adolescents,To confirm the doses for oral CAB followed by injectable CAB LA in HIV-infected, virologically suppressed adolescents by evaluating: Safety and multiple dose PK of oral CAB through Week 4, Safety and multiple dose PK of CAB LA through Week 16, and to confirm doses for injectable RPV LA in HIV-infected, virologically suppressed adolescents by evaluating safety and multiple dose PK of RPV LA through Week 16,To confirm the dose and evaluate the safety, tolerability, acceptability, and pharmacokinetics (PK) of oral cabotegravir (CAB), long-acting injectable cabotegravir (CAB LA), and long-acting injectable rilpivirine (RPV LA) in virologically suppressed HIVâ€1 infected children and adolescents aged 12 to <18 years.,
|
Uganda |
2021-08-16 |
2024-08-16 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Violet Korutaro
ID: UNCST-2019-R000618
|
IMPAACT Early Career Investigator Award entitled, “Breastmilk Biomarkers of Inflammation, Immune Activation, and Human Milk Oligosaccharides (HMOs) in Women with vs. without Vertical Transmission During Breastfeeding
REFNo: HS4086ES
1. Determine the concentrations of total and various composition of human milk oligosaccharides (HMOs) (lacto-N-fucopentaose; lacto-N-neotetraose; lacto-N- tetraose; 2#-fucosyllactose; 3-fucosyllactose; and three #-sialyllactose); Immunoglobulin isotypes and subclasses (IgG1, IgG2b, IgG2c, and IgG3) in breastmilk of WWH at delivery (up to 5-days) and 4-6 weeks postpartum.
2. Assess the associations of HMO composition and immunoglobulin subclasses with breastmilk-associated HIV transmission.
|
Uganda |
2024-04-26 9:53:07 |
2027-04-26 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Victoria Isika Kiasyo
ID: UNCST-2025-R017083
|
WOMEN'S DIGITAL SAFETY: Measurement for bolstering policy response
REFNo: SS3824ES
1. Conduct formative, human-centered research. We plan to co-create an instrument and contextualize our understanding of TFGBV, we will hold co-creation workshops with women and institutional stakeholders.
2. Translate formative human-centered findings to measurement. We will use qualitative insights from Aim 1 to compare local findings with existing TFGBV measures (developed mostly in high-income settings).
3. Pilot novel measure of TF-GBV exposure. We will pilot a quantitative instrument and submit this in an amendment to this ethics proposal. This amendment will specify the instrument, sampling, data collection procedures, analytical plan, community engagement and dissemination plan. Briefly, a long-list of items will be tested through quantitative surveys delivered both in person and digitally. Output from these surveys will enable us to validate and refine the instrument before dissemination.
|
Kenya |
2025-05-07 18:23:51 |
2028-05-07 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
Kisembo Vincent
ID: UNCST-2024-R003679
|
NATURAL RESOURCE GOVERNANCE AND HUMAN-ECOLOGICAL WELLBEING IN THE OIL AND GAS SUB SECTOR IN BUNYORO SUB-REGION
REFNo: SS2971ES
the study's main objective is to assess natural resource governance and human-ecological wellbeing in the oil and gas sub sector in Bunyoro sub-region, specifically in the districts of Hoima, Kikuube and Buliisa.
Specifically, the study aims to;
1. To analyse the established legal and institutional framework for oil natural resource governance in ensuring the well-being of human -ecological wellbeing in Buliisa, Hoima and Kikuube districts
2. To examine the policies on human wellbeing to the communities in the Oil and Gas sub sector in Buliisa, Hoima and Kikuube districts
3. To analyze the implications of oil and gas sub sector activities on ecological wellbeing in Buliisa, Hoima and Kikuube districts.
4. To examine social and environmental challenges emanating from Oil and gas activities in Buliisa, Hoima and Kikuube districts
|
Uganda |
2024-08-26 15:11:29 |
2027-08-26 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
VINCENT KIBERU MICHEAL
ID:
|
Implementing and evaluation of a low-resource digital infrastructure in Uganda: Visualization and Interpretation of Radiographic Images (VIoRI) to improve access to imaging services at Mulago and Kayunga regional referral hospitals.
REFNo: HS1287ES
a) To determine the diagnostic accuracy (specificity and sensitivity) of ordinary core i3 PC based display systems when compared to the dedicated PACS Workstations.
b) To determine the quality of JPEG images on ordinary core i3 PC’s compared to the DICOM images generated by the PACS workstations.
c) To determine the turnaround time of patient’s diagnosis processes using ordinary core i3 PC based digital display systems relative to the PACS workstations.
d) To strengthen research capacity and collaborations with the Ministry of Health so as to allow continuity of innovative digital health research that informs improved service provision.
|
Uganda |
2021-03-17 |
2024-03-17 |
Medical and Health Sciences |
|
Non-degree Award |
|
Viola Karungi
ID: UNCST-2024-R003996
|
ENOUGH! Vulnerability, Perseverance and Resistance in the 21st Century: a Docu-Drama Film about lived-experiences of Survivors of Gender-Based Violence in Uganda
REFNo: SS4572ES
To assess the aftermath of victimhood for the respondents.,To explore the copying mechanisms employed by the respondents to endure suffering. ,To examine the circumstances that led to domestic violence for the respondents. ,To analyze lived-experiences of victims/survivors of Gender-Based Violence in Kampala and Bushenyi.,
|
Uganda |
2026-01-19 16:54:10 |
2029-01-19 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Victor Kalenzi
ID:
|
Succession planning factors, transition process and the continuity of small and medium-size family businesses in Fort Portal City Uganda
REFNo: SS2862ES
i. To examine the influence of internal succession planning facets on family business continuity in Fort Portal Tourism City, Uganda.
ii. To assess the influence of external succession planning facets on family business continuity in Fort Portal Tourism City, Uganda.
iii. To investigate the mediating influence of succession process (transition) on the relationship between succession planning facets and family business community in Fort Portal Tourism City.
|
Uganda |
2024-08-29 18:50:55 |
2027-08-29 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|